37.47 USD
+1.61 (+4.49%)
We assign a fundamental rating of 3 out of 10 to LQDA. LQDA was compared to 190 industry peers in the Pharmaceuticals industry. LQDA has a bad profitability rating. Also its financial health evaluation is rather negative. LQDA shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
LQDA had negative earnings in the past year.
In the past year LQDA has reported a negative cash flow from operations.
In the past 5 years LQDA always reported negative net income.
LQDA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LQDA has a Return On Assets (-44.15%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -552.55%, LQDA is doing worse than 81.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.15% | ||
| ROE | -552.55% | ||
| ROIC | N/A |
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LQDA's Gross Margin of 89.11% is amongst the best of the industry. LQDA outperforms 91.05% of its industry peers.
LQDA's Gross Margin has declined in the last couple of years.
LQDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
2. Health
2.1 Basic Checks
LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LQDA has been increased compared to 1 year ago.
Compared to 5 years ago, LQDA has more shares outstanding
Compared to 1 year ago, LQDA has a worse debt to assets ratio.
2.2 Solvency
LQDA has an Altman-Z score of 3.63. This indicates that LQDA is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.63, LQDA is doing good in the industry, outperforming 68.95% of the companies in the same industry.
LQDA has a Debt/Equity ratio of 6.19. This is a high value indicating a heavy dependency on external financing.
LQDA has a worse Debt to Equity ratio (6.19) than 82.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.63 |
ROIC/WACCN/A
WACC9.34%
2.3 Liquidity
A Current Ratio of 2.20 indicates that LQDA has no problem at all paying its short term obligations.
LQDA has a Current ratio (2.20) which is in line with its industry peers.
A Quick Ratio of 1.96 indicates that LQDA should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.96, LQDA perfoms like the industry average, outperforming 43.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.2 | ||
| Quick Ratio | 1.96 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.66% over the past year.
Looking at the last year, LQDA shows a very strong growth in Revenue. The Revenue has grown by 343.41%.
The Revenue has been growing by 11.64% on average over the past years. This is quite good.
EPS 1Y (TTM)11.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
Revenue 1Y (TTM)343.41%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%1121.72%
3.2 Future
Based on estimates for the next years, LQDA will show a very strong growth in Earnings Per Share. The EPS will grow by 38.90% on average per year.
The Revenue is expected to grow by 124.26% on average over the next years. This is a very strong growth
EPS Next Y54.16%
EPS Next 2Y78.7%
EPS Next 3Y52.24%
EPS Next 5Y38.9%
Revenue Next Year845.19%
Revenue Next 2Y404.47%
Revenue Next 3Y231.27%
Revenue Next 5Y124.26%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LQDA. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 18.80 indicates a rather expensive valuation of LQDA.
Based on the Price/Forward Earnings ratio, LQDA is valued a bit cheaper than the industry average as 78.42% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of LQDA to the average of the S&P500 Index (23.92), we can say LQDA is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.8 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
LQDA's earnings are expected to grow with 52.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y78.7%
EPS Next 3Y52.24%
5. Dividend
5.1 Amount
No dividends for LQDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:LQDA (1/12/2026, 3:04:42 PM)
37.47
+1.61 (+4.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners72.57%
Inst Owner Change0.23%
Ins Owners3.84%
Ins Owner Change-1.86%
Market Cap3.26B
Revenue(TTM)69.22M
Net Income(TTM)-121.85M
Analysts82.67
Price Target44.88 (19.78%)
Short Float %17.59%
Short Ratio6.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)39.4%
Min EPS beat(2)-11.43%
Max EPS beat(2)90.23%
EPS beat(4)1
Avg EPS beat(4)11.84%
Min EPS beat(4)-20.44%
Max EPS beat(4)90.23%
EPS beat(8)2
Avg EPS beat(8)-9.9%
EPS beat(12)3
Avg EPS beat(12)-14.24%
EPS beat(16)5
Avg EPS beat(16)-16.1%
Revenue beat(2)2
Avg Revenue beat(2)148.62%
Min Revenue beat(2)114.23%
Max Revenue beat(2)183%
Revenue beat(4)2
Avg Revenue beat(4)63.27%
Min Revenue beat(4)-37.8%
Max Revenue beat(4)183%
Revenue beat(8)3
Avg Revenue beat(8)19.43%
Revenue beat(12)6
Avg Revenue beat(12)17%
Revenue beat(16)9
Avg Revenue beat(16)12.88%
PT rev (1m)0%
PT rev (3m)20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)183.82%
EPS NY rev (1m)13.01%
EPS NY rev (3m)53.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)114.3%
Revenue NY rev (1m)8.9%
Revenue NY rev (3m)116.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.8 | ||
| P/S | 47.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 147.83 | ||
| P/tB | 215.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.44
EYN/A
EPS(NY)1.99
Fwd EY5.32%
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.8
BVpS0.25
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.15% | ||
| ROE | -552.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.11% | ||
| FCFM | N/A |
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
F-Score4
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.19 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 410.55% | ||
| Cap/Sales | 10.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.2 | ||
| Quick Ratio | 1.96 | ||
| Altman-Z | 3.63 |
F-Score4
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)306.37%
Cap/Depr(5y)189%
Cap/Sales(3y)42.88%
Cap/Sales(5y)46.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
EPS Next Y54.16%
EPS Next 2Y78.7%
EPS Next 3Y52.24%
EPS Next 5Y38.9%
Revenue 1Y (TTM)343.41%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%1121.72%
Revenue Next Year845.19%
Revenue Next 2Y404.47%
Revenue Next 3Y231.27%
Revenue Next 5Y124.26%
EBIT growth 1Y3.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-158.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-233.81%
OCF growth 3YN/A
OCF growth 5YN/A
LIQUIDIA CORP / LQDA FAQ
What is the ChartMill fundamental rating of LIQUIDIA CORP (LQDA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to LQDA.
What is the valuation status of LIQUIDIA CORP (LQDA) stock?
ChartMill assigns a valuation rating of 3 / 10 to LIQUIDIA CORP (LQDA). This can be considered as Overvalued.
What is the profitability of LQDA stock?
LIQUIDIA CORP (LQDA) has a profitability rating of 1 / 10.
What is the financial health of LIQUIDIA CORP (LQDA) stock?
The financial health rating of LIQUIDIA CORP (LQDA) is 3 / 10.